Interleukin Gen launches series of genetic tests

8 June 2009

USA-based Interleukin Genetics has launched its new Inherent Health brand of genetic tests and related programs including the  first-of-its-kind test for weight management that identifies an  individual's genetic tendencies for weight gain and metabolism.

The firm says the Inherent Health brand offers customers a full suite of  affordable, easy-to-use and meaningful genetic tests in heart health,  bone health and nutritional needs, as well as PST, the periodontal  disease risk assessment test. The products permit focused, personalized  guidance for individuals looking for insights on specific lifestyle  changes that can be made based on their genetic results to impact their  health and wellness.

Other products in the range include: the Heart Health Genetic Test,  which identifies a person's genetic predisposition to heart attack based  on inflammation; Nutritional Needs Genetic Test, which identifies DNA  variations in genes crucial to B-vitamin metabolism and the ability to  manage oxidative stress; and the Bone Health Genetic Test, which will be  available during the second half of this year and will identify whether  an individual is more likely to be susceptible to spine fractures and  low bone mineral density-associated with osteoporosis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight